Dr. Carter P. Milner, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Mississippi School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 317
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Mississippi School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MS license 21333 -
Internal Medicine Physician
MS license T-2099
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mississippi Baptist Medical Center Jackson, MS
- University of Mississippi Med Center Jackson, MS
- Forrest General Hospital Hattiesburg, MS
- Merit Health River Region Vicksburg, MS
- Merit Health Madison Canton, MS
Medical groups
- State of Mississippi - University of Mississippi Medical Center (965 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 317
- Services billed
- 1,256
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 369 | 162 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 311 | 52 |
| Established patient office or other outpatient visit, 40-54 minutes | 173 | 56 |
| Established patient office or other outpatient visit, 20-29 minutes | 121 | 98 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 42 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 37 | 20 |
| Hospital discharge day management, more than 30 minutes | 37 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Jackson, MS | 149 |
| Gabapentin Other prescribers in Jackson, MS | 116 |
| Pantoprazole Sodium Other prescribers in Jackson, MS | 113 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Jackson, MS | 107 |
| Allopurinol Other prescribers in Jackson, MS | 92 |
| Lenalidomide | 82 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Jackson, MS | 75 |
| Potassium Chloride Other prescribers in Jackson, MS | 74 |
| Levofloxacin Other prescribers in Jackson, MS | 60 |
| Revlimid (lenalidomide) | 57 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 99 payments worth $25,692 in total to this clinician.
| Beone Medicines USA, Inc. | $11,040 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $8,937 |
| Janssen Biotech, Inc. | $3,656 |
| AstraZeneca Pharmaceuticals LP | $646 |
| Celgene Corporation | $273 |
| Novartis Pharmaceuticals Corporation | $131 |
| Pfizer Inc. | $125 |
| Incyte Corporation | $97.01 |
| Compensation for services other than consulting (speaking, faculty) | $19,878 |
|---|---|
| Consulting Fee | $2,840 |
| Food and Beverage | $1,917 |
| Travel and Lodging | $1,057 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $5,460 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $5,200 |
| Beone Medicines USA, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $3,900 |
| E.r. Squibb & Sons, L.l.c. May 12, 2025 | Consulting Fee | $2,840 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,138 |
| Janssen Biotech, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Janssen Biotech, Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Janssen Biotech, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Janssen Biotech, Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $550 |
| Janssen Biotech, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $440 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Janssen Biotech, Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $440 |
| Janssen Biotech, Inc. Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $550 |
| Janssen Biotech, Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| Janssen Biotech, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $880 |
| E.r. Squibb & Sons, L.l.c. May 12, 2025 | Consulting Fee | $2,840 |
| Beone Medicines USA, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $3,900 |
| E.r. Squibb & Sons, L.l.c. May 5, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Biloxi, MS | $276 |
| E.r. Squibb & Sons, L.l.c. May 5, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Biloxi, MS | $232 |
| E.r. Squibb & Sons, L.l.c. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $5,460 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $5,200 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,138 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Fairhope, AL | $298 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Fairhope, AL | $250 |
| AstraZeneca Pharmaceuticals LP Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $540 in research payments for these studies, mostly to the institutions running them.
- A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.